| Acute Leukemia |
1 |
1 |
| Acute Myeloblastic Leukemia |
0 |
0.77 |
| Biologic Therapy |
0 |
0.76 |
| Chronic Lymphocytic Leukemia |
0 |
0.7 |
| Leukemia |
0 |
0.57 |
| Chronic Myelogenous Leukemia |
0 |
0.54 |
| Myelodysplastic Syndrome |
0 |
0.54 |
| Stem Cell Research and Therapy |
0 |
0.52 |
| Transplantation |
0 |
0.36 |
| Cell Transplantation |
0 |
0.35 |
| Antineoplastic Drug |
0 |
0.24 |
| California |
0 |
0.21 |
| Chemotherapy |
0 |
0.21 |
| Monoclonal Antibody |
0 |
0.21 |
| New York |
0 |
0.21 |
| Tyrosine Kinase |
0 |
0.21 |
| Tyrosine Kinase Inhibitor |
0 |
0.21 |
| Cancer |
0 |
0.19 |
| Child |
0 |
0.14 |
| Florida |
0 |
0.14 |
| Lymphoma |
0 |
0.14 |
| Missouri |
0 |
0.14 |
| Texas |
0 |
0.14 |
| Systemic Mastocytosis |
0 |
0.1 |
| Blood |
0 |
0.07 |
| Clinical Research |
0 |
0.99 |
| Intravenous |
0 |
0.07 |
| Louisiana |
0 |
0.07 |
| Massachusetts |
0 |
0.07 |
| Mastocytosis |
0 |
0.07 |
| Neoplasm |
0 |
0.07 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.07 |
| Ohio |
0 |
0.07 |
| Oklahoma |
0 |
0.07 |
| Pennsylvania |
0 |
0.07 |
| Pharmacodynamics |
0 |
0.07 |
| Quality of Life |
0 |
0.07 |
| Radiation Therapy |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Residual Disease |
0 |
0.07 |
| South Carolina |
0 |
0.07 |
| Tennessee |
0 |
0.07 |
| Utah |
0 |
0.07 |
| Virginia |
0 |
0.07 |
| Young Adult |
0 |
0.07 |